Short Interest in BioStem Technologies, Inc. (OTCMKTS:BSEM) Declines By 21.2%

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 117,700 shares, a drop of 21.2% from the November 15th total of 149,400 shares. Based on an average trading volume of 197,300 shares, the short-interest ratio is presently 0.6 days.

BioStem Technologies Stock Up 5.9 %

BioStem Technologies stock traded up 0.97 during midday trading on Friday, reaching 17.21. The stock had a trading volume of 60,600 shares, compared to its average volume of 38,093. BioStem Technologies has a 52-week low of 4.28 and a 52-week high of 28.26. The company has a fifty day moving average of 15.25 and a 200 day moving average of 11.51. The firm has a market cap of $286.05 million, a price-to-earnings ratio of 25.31 and a beta of -0.62.

BioStem Technologies (OTCMKTS:BSEM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported 0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of 0.31 by 0.01. The business had revenue of 82.56 million for the quarter, compared to analysts’ expectations of 78.22 million. Equities research analysts predict that BioStem Technologies will post 1.41 EPS for the current year.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.